Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Dexamethasone sodium phosphate loaded polymeric nanoparticles for treating nitrogen mustard induced corneal injury
Author Affiliations & Notes
  • Sagun Poudel
    Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia, United States
  • Ehsan Kaffash
    Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia, United States
  • Divya Bande
    Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia, United States
  • Rudra Pangeni
    Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia, United States
  • Long Zhao
    Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia, United States
  • Qingguo Xu
    Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia, United States
  • Footnotes
    Commercial Relationships   Sagun Poudel None; Ehsan Kaffash None; Divya Bande None; Rudra Pangeni None; Long Zhao None; Qingguo Xu US 10195212, Code P (Patent)
  • Footnotes
    Support  R01EY027827
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 3660. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sagun Poudel, Ehsan Kaffash, Divya Bande, Rudra Pangeni, Long Zhao, Qingguo Xu; Dexamethasone sodium phosphate loaded polymeric nanoparticles for treating nitrogen mustard induced corneal injury. Invest. Ophthalmol. Vis. Sci. 2024;65(7):3660.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Nitrogen mustard (NM) is a potent vesicating chemical warfare agent that causes severe corneal injuries leading to inflammation, ulceration, neovascularization etc. Effective treatment therapies for vesicant-induced ocular injuries are not yet available. To address this potential threat, we engineered biodegradable polymeric nanoparticles (NPs) loaded with water-soluble dexamethasone sodium phosphate (DSP) or PLGA-DSP-NP. We aim to achieve sustained anti-inflammatory and anti-angiogenic effects for preventing NM-induced corneal injury following a single subconjunctival (SCT) injection.

Methods : PLGA-DSP-NP was formulated using Poly (lactic-co-glycolic acid) (PLGA 7kDa) via a zinc ion bridge method. PLGA-DSP-NP was characterized for particle size, surface charge, morphology, drug loading and in vitro drug release profile. NM-induced corneal injury model was set up by exposing adult Sprague Dawley rats’ eye with 1% NM for 1 minute. NM exposed rats were immediately treated with a single PLGA-DSP-NP SCT injection (180µg DSP) following NM exposure and followed for two weeks. As controls, NM treated rats with SCT injected DSP solution, saline, placebo NPs or DSP eyedrops were considered. Routine clinical observations and evaluations for corneal opacity, corneal ulceration, corneal neovascularization was performed till D14. mRNA expression level of inflammatory and angiogenic cytokines were quantified using qPCR at D14.

Results : PLGA-DSP-NP had particle size of 250 ± 2.5 nm and surface charge of -3.6 ± 0.2 mV (Fig 1A). DSP-NP had 6.5 wt% drug loading and sustained in vitro drug release for two weeks (Fig 1B). NM exposed rats (1%, 1min) possessed significant ulceration (p<0.001), neovascularization and opacity at D14 compared to healthy cornea. Efficacy study using PLGA-DSP-NPs in NM exposed rats demonstrated that the single SCT injection of nanoparticles significantly prevented corneal ulceration (p<0.01) (Fig 1C), corneal neovascularization (p<0.001) (Fig 1D), corneal opacity (p<0.001), and prevented the corneal epithelial depletion compared to saline group. It was also evident from a significantly reduced expression of inflammatory and angiogenic cytokines (IFN-γ, IL-6, MMP-9, VEGF etc).

Conclusions : The SCT injection of PLGA-DSP-NP can be a promising strategy for vesicant-induced corneal injuries with improved patient adherence and easy translational possibilities.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×